American Well (NYSE:AMWL) Insider Sells $30,299.49 in Stock

American Well Corporation (NYSE:AMWL) insider Phyllis Gotlib sold 4,959 shares of the business’s stock in a transaction on Wednesday, October 1st. The stock was sold at an average price of $6.11, for a total value of $30,299.49. Following the transaction, the insider owned 127,151 shares in the company, valued at approximately $776,892.61. This trade represents a 3.75% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Phyllis Gotlib also recently made the following trade(s):

• On Tuesday, September 2nd, Phyllis Gotlib sold 4,781 shares of American Well stock. The stock was sold at an average price of $6.78, for a total value of $32,415.18.

American Well Stock Up 3.6%

AMWL opened at $6.34 on Monday. The company has a market cap of $102.39 million, a P/E ratio of -0.79 and a beta of 1.26. The firm’s 50-day moving average price is $6.92 and its 200-day moving average price is $7.27. American Well Corporation has a 52-week low of $5.98 and a 52-week high of $12.95.

American Well (NYSE:AMWL) last posted its quarterly earnings results on Tuesday, August 5th. The company reported ($1.24) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.84) by $0.60. The business had revenue of $70.90 million during the quarter, compared to analysts’ expectations of $63.87 million. American Well had a negative net margin of 46.15% and a negative return on equity of 41.99%. American Well has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. On average, research analysts anticipate that American Well Corporation will post -9.34 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

AMWL has been the topic of several analyst reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of American Well in a research report on Saturday, September 27th. Wells Fargo & Company lowered their target price on American Well from $15.00 to $12.00 and set an “overweight” rating on the stock in a research note on Thursday, August 7th. One equities research analyst has rated the stock with a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $9.17.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of AMWL. Senvest Management LLC grew its position in shares of American Well by 0.3% during the 2nd quarter. Senvest Management LLC now owns 1,312,852 shares of the company’s stock valued at $11,671,000 after acquiring an additional 4,497 shares during the period. Acadian Asset Management LLC boosted its position in American Well by 19.5% during the first quarter. Acadian Asset Management LLC now owns 188,217 shares of the company’s stock worth $1,481,000 after purchasing an additional 30,669 shares in the last quarter. Goldman Sachs Group Inc. boosted its position in American Well by 280.6% during the first quarter. Goldman Sachs Group Inc. now owns 64,760 shares of the company’s stock worth $510,000 after purchasing an additional 47,745 shares in the last quarter. Jane Street Group LLC grew its holdings in American Well by 232.9% in the first quarter. Jane Street Group LLC now owns 64,112 shares of the company’s stock valued at $505,000 after purchasing an additional 44,852 shares during the period. Finally, Two Sigma Advisers LP increased its position in shares of American Well by 102.7% in the fourth quarter. Two Sigma Advisers LP now owns 41,045 shares of the company’s stock valued at $298,000 after buying an additional 20,800 shares in the last quarter. Institutional investors and hedge funds own 56.05% of the company’s stock.

About American Well

American Well Corporation, an enterprise platform and software company, delivers digitally enabling hybrid care in the United States and internationally. The company offers Converge, a cloud-based platform that enables health providers, payers, and innovators to provide in-person, virtual and automated care; and delivers virtual primary care, post-discharge follow-up, chronic condition management, virtual nursing, e-sitting, on-demand and scheduled virtual visits, specialty consults, automated care, and behavioral health, as well as specialty care programs, including dermatology, musculoskeletal care, second opinion, and cardiometabolic care to patients and members.